Vijaya Diagnostic Centre Ltd. announces an acquisition

Assuming “Arya Health Services” refers to Arya Wellness Centre, Vijaya’s disclosed transaction value is approximately Rs 46 Crores for the 100% integrated diagnostic business acquired through a slump sale. The transaction was announced on 11 September 2026, with completion indicated for November/December 2026, so this is the agreed consideration rather than necessarily a completed cash payment. ^[1]

Valuation calculation

• FY26 revenue: Rs 26 Crores; FY26 EBITDA: Rs 5.6 Crores (INR 56 million). ^[2]
• Implied EV: approximately Rs 46 Crores, used as the transaction-value proxy because the disclosure provides consideration but no separate debt/cash bridge.
• Implied EV/EBITDA: Rs 46 Crores ÷ Rs 5.6 Crores = 8.21x, derived from the disclosed figures.
• This is consistent with Vijaya’s stated transaction valuation range of approximately 8–9x EBITDA. ^[1]

Comparison with Vijaya’s historical acquisition benchmarks

A like-for-like comparison cannot be established from the cited disclosures: prior Vijaya acquisition prices and corresponding EBITDA multiples are not reported. Therefore, it is not possible to conclude whether the 8.2x multiple is above or below Vijaya’s historical acquisition benchmarks.

The defensible conclusion is narrower: Arya was priced at roughly 8.2x FY26 EBITDA, within Vijaya’s disclosed 8–9x transaction range; no verified historical acquisition multiple is available for comparison. Also, this is a slump-sale acquisition of a business undertaking rather than clearly a purchase of the target company’s equity shares. ^[3]

Arya Health Services’ standalone annual revenue and EBITDA margin are not separately reported in the cited disclosures, so a reliable Arya-specific figure cannot be calculated.

• Closest reported parent-company reference: Vijaya Diagnostic Centre’s consolidated TTM revenue was Rs 857.13 Crores as of Q1 FY27 ^[4], with a consolidated TTM EBITDA margin of 44.80% ^[5]. These figures should not be attributed to Arya Health Services.
• Operational synergy and brand integration: No target date or phased timeline is disclosed. The acquisition reference says Vijaya’s transaction enables integration of PH Diagnostic, but it does not specify when operational synergies or brand integration are expected to be completed ^[6].

Conclusion: Arya-specific revenue, EBITDA margin, and the synergy/brand-integration timeline remain undisclosed in the cited financial material.

Verdict: Guwahati appears strategically compatible with Vijaya’s integrated, B2C-led model, but its disclosed mix is more pathology-heavy than a pure advanced-imaging proposition. The pricing comparison is less conclusive: management has disclosed pricing pressure and limited recent price increases in the core markets, while Guwahai-specific price levels have not been reported. No separate capital-expenditure budget for scaling the North-East has been disclosed.

Test mix and customer profile

Arya Wellness Centre’s FY26 revenue mix was:

The facility is therefore balanced across modalities, but with a modest pathology bias. It also has a high B2C orientation: more than 85% of business comes from B2C customers, supported by established pathology and radiology clinicians ^[2]. This is directionally consistent with Vijaya’s core model, where B2C contributed 92% of revenue in Q1 FY27, and the integrated offering generated approximately 3.7 tests per footfall and Rs 1,860 revenue per footfall ^[7].

The important caveat is that Vijaya has not disclosed a comparable consolidated radiology-pathology split for its South Indian operations. Accordingly, Guwahati’s 44:56 mix cannot be described as higher or lower than the core regions on a like-for-like basis.

Pricing environment

The core-market benchmark points to a competitive environment rather than broad-based pricing power. Management said the last price increase was in June 2025 and was limited to selected tests in Hyderabad; no subsequent price increase had been taken, with pricing to be reassessed after Q2/Q3 ^[8]. Vijaya’s core economics are supported more visibly by B2C mix, cross-selling and radiology-pathology integration than by frequent tariff increases.

For Guwahati, the acquired centre’s approximately 80% gross margin and approximately 21% EBITDA margin indicate an established, relatively attractive operating profile ^[9]. However, the presentation does not provide Guwahati-specific tariffs, realization per test, volume discounts, or competitor pricing. The defensible conclusion is therefore that Guwahati has a favourable B2C and specialty-service setup, but its pricing premium versus Hyderabad or other South Indian markets remains unproven.

Capital required for the new geography

• The announced transaction consideration is approximately Rs 46 Crores, structured as a slump-sale acquisition and to be funded through internal accruals ^[1].
• That Rs 46 Crores is the acquisition price, not a separately identified post-acquisition capex budget.
• Management described the expansion beyond the acquired platform as a “calibrated expansion strategy”, but no quantified capex allocation for additional Guwahati centres, spokes, equipment or reference-lab expansion was disclosed ^[10].

Implication: Vijaya is entering Guwahati with an operating asset rather than building the geography from scratch, limiting immediate greenfield capex risk. The larger uncertainty is the amount and timing of incremental investment needed to replicate its hub-and-spoke model across Assam and the wider North-East; that commitment is not yet quantified.